✦ LIBER ✦

Treatment of two mastocytosis patients with a histidine decarboxylase inhibitor

✍ Scribed by G. Granerus; J. H. Olafsson; G. Roupe

Publisher: SP Birkhäuser Verlag Basel
Year: 1985
Tongue: English
Weight: 412 KB
Volume: 16
Category: Article
ISSN: 1420-908X
DOI: 10.1007/bf01983151

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Two patients with osteoporosis: initial

Two patients with osteoporosis: initial presentation of systemic mastocytosis

✍ Marjolein L. Donker; Nicolaas A. Bakker; Wim J. M. Jaspers; Albert H. Verhage 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 230 KB

Psychomotor effects of L-DOPA combined w

Psychomotor effects of L-DOPA combined with a decarboxylase inhibitor on parkinsonian patients

✍ R. Klaiber; J. Siegfried; W. H. Ziegler; E. Perret 📂 Article 📅 1971 🏛 Springer 🌐 English ⚖ 344 KB

Treatment of two patients with acquired

Treatment of two patients with acquired factor VIII inhibitors using cyclophosphamide and prednisone

✍ Mark S. Hertzberg; Emmanuel Favaloro; Jerry Koutts 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 2 views

Treatment of acquired factor VIII inhibi

Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus

✍ Thomas E. Lafferty; J. Bruce Smith; Stephen J. Schuster; Raphael J. Dehoratius 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 401 KB 👁 1 views

Investigation of two variants in the DOP

Investigation of two variants in the DOPA decarboxylase gene in patients with autism

✍ Lauritsen, Marlene B. ;Børglum, Anders D. ;Betancur, Catalina ;Philippe, Anne ;K 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

Levodopa alone and in combination with a

Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease

✍ U. K. Rinne; E. Birket-Smith; E. Dupont; E. Hansen; M. Hyyppä; R. Marttila; B. M 📂 Article 📅 1975 🏛 Springer 🌐 English ⚖ 528 KB

A combination of levodopa and the extracerebrally acting decarboxylase inhibitor benserazide (ratio 4:1) (Madopar), was compared with levodopa alone in a controlled double-blind clinical multicenter trial on 94 patients with Parkinson's disease. During 4 months of therapy levodopa + benserazide prov